asenapine has been researched along with Schizophrenia in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (14.29) | 29.6817 |
| 2010's | 54 (70.13) | 24.3611 |
| 2020's | 12 (15.58) | 2.80 |
| Authors | Studies |
|---|---|
| Shahid, M; Walker, GB; Wong, EH; Zorn, SH | 1 |
| Hibino, H; Inoue, Y; Matsumoto, H; Mikami, K; Suzuki, H; Takaya, A; Yamamoto, K | 2 |
| Abdel-Mottaleb, MMA; El-Ghany, EA; El-Tokhy, FS; Geneidi, AS | 1 |
| Choudhury, H; Dalal, R; Gorain, B; Jacob, S; Mehta, TA; Nair, AB; Shah, H; Shah, J | 1 |
| Hiraoka, S; Iwama, Y; Iwata, N; Kamei, A; Kishi, T; Sasagawa, Y | 1 |
| Hiraoka, S; Iwama, Y; Kinoshita, T; Takekita, Y; Tamura, F | 1 |
| Graff-Guerrero, A; Kurose, S; Masuda, F; Mimura, M; Mimura, Y; Miyazaki, T; Nakajima, S; Nishida, H; Noda, Y; Ogyu, K; Plitman, E; Tarumi, R; Tsugawa, S; Uchida, H; Wada, M; Yoshida, K | 1 |
| Barlow, R; Bertrand, S; Cornett, EM; DeGraw, C; Derakhshanian, S; Hasoon, J; Kaye, AD; Kaye, AM; Menard, A; Rath, A; Urits, I; Viswanath, O; Zhou, M | 1 |
| Citrome, L; Komaroff, M; Kuriki, M; Park, AS; Starling, BR; Terahara, T; Walling, DP; Zeni, CM | 1 |
| Chen, JM; Chen, JN; Li, Y; Liu, RH; Meng, FL; Meng, TT; Ning, B; Su, GH; Wang, SY; Wu, HH | 1 |
| Fujiwara, H; Murai, T; Takao, N | 1 |
| Luck, M; Shad, MU; Turner, M | 1 |
| Findling, RL; Grant, B; Stepanova, E | 1 |
| Augusto, M; Greene, M; Sweeney, SM; Touya, M; Waters, H | 1 |
| Hibino, H; Inoue, Y; Suzuki, H; Takaya, A | 1 |
| Mishriky, R; Reyad, AA | 1 |
| Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM | 1 |
| Rasmussen, KG; Swintak, CC; Vande Voort, JL; Wall, CA | 1 |
| Bressan, RA; Castle, DJ; Cortese, L; Mosolov, SN | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Alphs, L; Cazorla, P; Phiri, P; Potkin, SG; Szegedi, A; Zhao, J | 1 |
| Leucht, S; Zhao, J | 1 |
| Cazorla, P; Kemp, DE; Landbloom, RP; Mackle, M; Snow-Adami, L; Szegedi, A; Zhao, J | 1 |
| Beauchemin, C; Beillat, M; Gilbert, D; Lachaine, J; Mathurin, K | 1 |
| Dhillon, R; Kotasek, F; Tibrewal, P | 1 |
| Citrome, L | 4 |
| Castle, DJ; Slott Jensen, JK | 1 |
| Bastiampillai, T; Chen, L; Dhillon, R; Lim, X; Lin, A; Tibrewal, P | 1 |
| Mandrioli, R; Mercolini, L; Protti, M | 1 |
| Braat, S; Findling, RL; Hundt, C; Landbloom, RP; Mackle, M; Mathews, M; Pallozzi, W; Wamboldt, MZ | 1 |
| Hamer, R; McEvoy, J; Sun, X | 1 |
| Caballero, J; Harrington, CA; Thomas, JE | 1 |
| Barr, A; Rodriguez, FV; Schultz, K; Wang, L | 1 |
| Basra, MK; Byers, A; Dutta, S; Hay, A; Sereno, M | 1 |
| Anugu, RR; Chandrasekhar, S; Mainkar, PS; Sridhar, B | 1 |
| Boulanger, L; Chitnis, A; Dixit, S; Sun, SX; Tawah, A; Wang, R | 1 |
| Bhattacharya, A; Bhuyan, D; Ghosh, S; Praharaj, SK | 1 |
| Bai, YM; Kim, JH; Kinoshita, T; Miyake, M; Oshima, N | 1 |
| Hundt, C; Kelly, L; Landbloom, R; Mackle, M; Mathews, M; McIntyre, RS; Snow-Adami, L; Wu, X | 1 |
| de Greef, R; Friberg, LE; Karlsson, MO; Kerbusch, T | 1 |
| McCormack, PL; Weber, J | 1 |
| Traynor, K | 1 |
| Bockbrader, H; Chapel, S; de Greef, R; Haig, G; Hutmacher, MM; Lalonde, RL; Preskorn, SH | 1 |
| Dritselis, A; Kirkpatrick, P; Meltzer, HY; Yasothan, U | 1 |
| Shahid, M; Tarazi, FI | 1 |
| Emsley, R; Naber, D; Panagides, J; Schoemaker, J; Vrijland, P | 1 |
| Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J | 1 |
| Minassian, A; Young, JW | 1 |
| Bockbrader, H; Chapel, S; de Greef, R; Hutmacher, MM; Lalonde, RL | 1 |
| de Greef, R; Maloney, A; Olsson-Gisleskog, P; Panagides, J; Schoemaker, J | 1 |
| Roman, MW | 1 |
| Kane, JM; Mackle, M; Panagides, J; Snow-Adami, L; Szegedi, A; Zhao, J | 1 |
| Howland, RH | 1 |
| Ambrosi, E; Battuello, M; Giordano, G; Girardi, P; Innamorati, M; Lester, D; Pompili, M; Serafini, G; Telesforo, L; Venturini, P | 1 |
| de Greef, R; Dubovsky, SL; Frobose, C; Panagides, J; Phiri, P | 1 |
| Fuller, MA; Henry, JM | 1 |
| McIntyre, RS; Wong, R | 1 |
| Alphs, L; Buchanan, RW; Cazorla, P; den Hollander, W; Ha, X; Kouassi, A; Panagides, J; Phiri, P; Schooler, N; Szegedi, A; Zhao, J | 1 |
| Potkin, SG | 1 |
| Emsley, R; Naber, D; Panagides, J; Schoemaker, J; Stet, L; Vrijland, P | 1 |
| Pace, HA; Stoner, SC | 1 |
| Hopkins, CR | 1 |
| Stahl, SM; Tarazi, FI | 1 |
| Correll, CU; De Hert, M; Detraux, J; Sweers, K; van Winkel, R; Yu, W | 1 |
| Neill, JC; Tarazi, FI | 1 |
| Bobo, WV | 1 |
| Cazorla, P; Fennema, H; Mackle, M; Szegedi, A; van Duijnhoven, W; Verweij, P | 1 |
| Alphs, L; Lancaster, S; Panagides, J | 1 |
| Frånberg, O; Jardemark, K; Konradsson, A; Marcus, MM; Schilström, B; Shahid, M; Svensson, TH; Wiker, C; Wong, EH | 1 |
| Cohen, M; Panagides, J; Potkin, SG | 1 |
28 review(s) available for asenapine and Schizophrenia
| Article | Year |
|---|---|
Asenapine Transdermal Patch for the Management of Schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Quality of Life; Schizophrenia; Transdermal Patch | 2020 |
In brief: An asenapine patch (Secuado) for schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Schizophrenic Psychology; Transdermal Patch | 2021 |
Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Double-Blind Method; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Treatment Outcome | 2018 |
Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
Topics: Antipsychotic Agents; Bipolar Disorder; Borderline Personality Disorder; Dibenzocycloheptenes; Europe; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; United States | 2019 |
Management of schizophrenia: clinical experience with asenapine.
Topics: Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2013 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Schizophrenia; Sensitivity and Specificity; Treatment Outcome | 2014 |
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Controlled Clinical Trials as Topic; Dibenzocycloheptenes; Female; Hematologic Tests; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2014 |
Asenapine review, part II: clinical efficacy, safety and tolerability.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Electrocardiography; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2014 |
Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.
Topics: Antipsychotic Agents; Bipolar Disorder; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Dibenzocycloheptenes; Drug Interactions; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2014 |
Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Drug Design; Drug Monitoring; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis.
Topics: Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripiprazole; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Incidence; Lurasidone Hydrochloride; Schizophrenia | 2015 |
Asenapine versus placebo for schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2015 |
Asenapine.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2009 |
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Topics: Administration, Sublingual; Antipsychotic Agents; Bipolar Disorder; Cytochrome P-450 Enzyme System; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2009 |
Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Dibenzocycloheptenes; Drug Evaluation, Preclinical; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2009 |
Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Controlled Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Weight Gain | 2010 |
Evaluation of the clinical efficacy of asenapine in schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Dopamine Antagonists; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2010 |
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2011 |
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Medication Adherence; Schizophrenia | 2011 |
Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Treatment Outcome | 2012 |
Asenapine: a clinical overview.
Topics: Antipsychotic Agents; Blood Glucose; Dibenzocycloheptenes; Dyslipidemias; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; Treatment Outcome; Weight Gain | 2011 |
Asenapine: a clinical review of a second-generation antipsychotic.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Psychiatric Status Rating Scales; Schizophrenia; Secondary Prevention | 2012 |
Iloperidone, asenapine and lurasidone: a primer on their current status.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lipid Metabolism; Lurasidone Hydrochloride; Paliperidone Palmitate; Piperidines; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Weight Gain | 2012 |
The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Evaluation, Preclinical; Heterocyclic Compounds, 4 or More Rings; Humans; Neurotransmitter Agents; Schizophrenia | 2013 |
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2013 |
Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Topics: Acute Disease; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Psychiatric Status Rating Scales; Psychometrics; Randomized Controlled Trials as Topic; Risk Assessment; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2012 |
19 trial(s) available for asenapine and Schizophrenia
| Article | Year |
|---|---|
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Humans; Schizophrenia; Treatment Outcome | 2023 |
Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication.
Topics: Antipsychotic Agents; Follow-Up Studies; Humans; Schizophrenia | 2023 |
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Time Factors; Treatment Outcome | 2020 |
Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
Topics: Adult; Aged; Antipsychotic Agents; Dibenzocycloheptenes; Double-Blind Method; Female; Humans; Male; Middle Aged; Schizophrenia; Single-Blind Method; Transdermal Patch; Treatment Outcome | 2020 |
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult | 2013 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocycloheptenes; Double-Blind Method; Female; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2015 |
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Child; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2015 |
Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Satisfaction; Schizophrenia; Young Adult | 2015 |
Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Asian People; Body Weight; Dibenzocycloheptenes; Double-Blind Method; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Republic of Korea; Safety; Schizophrenia; Taiwan; Treatment Outcome | 2016 |
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzocycloheptenes; Disease Progression; Disorders of Excessive Somnolence; Dizziness; Double-Blind Method; Dysgeusia; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Hypesthesia; Least-Squares Analysis; Male; Mouth Diseases; Olanzapine; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain | 2017 |
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Linear Models; Long QT Syndrome; Male; Middle Aged; Schizophrenia; Time Factors | 2009 |
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Double-Blind Method; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Dibenzocycloheptenes; Double-Blind Method; Female; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Parkinsonian Disorders; Schizophrenia; Treatment Outcome | 2010 |
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.
Topics: Antipsychotic Agents; Arrhythmias, Cardiac; Bias; Computer Simulation; Data Interpretation, Statistical; Dibenzocycloheptenes; Dibenzothiazepines; Dose-Response Relationship, Drug; False Positive Reactions; Heterocyclic Compounds, 4 or More Rings; Humans; Models, Biological; Pharmacology, Clinical; Practice Guidelines as Topic; Quetiapine Fumarate; Schizophrenia; Toxicity Tests | 2011 |
A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Anxiety; Dibenzocycloheptenes; Double-Blind Method; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Secondary Prevention; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult | 2011 |
Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Area Under Curve; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Psychotic Disorders; Schizophrenia | 2012 |
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzocycloheptenes; Double-Blind Method; Drug Resistance; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Interpersonal Relations; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychomotor Performance; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult | 2012 |
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Diagnostic and Statistical Manual of Mental Disorders; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Pharmacovigilance; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Time; Treatment Outcome; Weight Gain | 2012 |
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Dibenzocycloheptenes; Double-Blind Method; Drug Administration Schedule; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Patient Compliance; Risperidone; Schizophrenia; Severity of Illness Index | 2007 |
30 other study(ies) available for asenapine and Schizophrenia
| Article | Year |
|---|---|
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Histamine Release; Humans; Inhibitory Concentration 50; Molecular Structure; Olanzapine; Psychotropic Drugs; Radioligand Assay; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Schizophrenia; Substrate Specificity | 2009 |
Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Schizophrenia; Thiophenes | 2021 |
Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia.
Topics: Administration, Cutaneous; Animals; Biological Availability; Dibenzocycloheptenes; Drug Delivery Systems; Female; Particle Size; Rats; Rats, Wistar; Schizophrenia; Skin | 2021 |
Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2021 |
Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Retrospective Studies; Schizophrenia; Thiophenes; Treatment Outcome | 2021 |
Asenapine maleate inhibits angiotensin II-induced proliferation and activation of cardiac fibroblasts via the ROS/TGFβ1/MAPK signaling pathway.
Topics: Angiotensin II; Animals; Cell Differentiation; Cell Proliferation; Cell Survival; Dibenzocycloheptenes; Fibroblasts; Fibrosis; MAP Kinase Signaling System; Myocardium; Rats; Rats, Wistar; Reactive Oxygen Species; Schizophrenia; Transforming Growth Factor beta1 | 2021 |
Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Dopamine; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2021 |
Effectiveness of genetically-guided treatment in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Pharmacogenetics; Schizophrenia; Young Adult | 2018 |
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Budgets; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzocycloheptenes; Drug Administration Schedule; Drug Costs; Health Care Costs; Heterocyclic Compounds, 4 or More Rings; Hospitalization; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medication Adherence; Paliperidone Palmitate; Piperazines; Schizophrenia | 2018 |
Mortality rate is associated with aripiprazole once-monthly and oral asenapine administration.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Retrospective Studies; Schizophrenia; Suicide | 2019 |
Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Delta Rhythm; Dibenzocycloheptenes; Disease Models, Animal; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Rats; Rats, Sprague-Dawley; Schizophrenia | 2019 |
Methohexital-induced seizures during electroconvulsive therapy.
Topics: Adolescent; Anesthesia; Anesthetics, Intravenous; Antipsychotic Agents; Depressive Disorder, Major; Dibenzocycloheptenes; Electroconvulsive Therapy; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Methohexital; Schizophrenia; Seizures; Social Behavior | 2013 |
Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Topics: Antipsychotic Agents; Canada; Cost-Benefit Analysis; Decision Trees; Dibenzocycloheptenes; Health Services; Heterocyclic Compounds, 4 or More Rings; Humans; Markov Chains; Models, Economic; Schizophrenia | 2014 |
QTc prolongation with asenapine.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Long QT Syndrome; Male; Middle Aged; Schizophrenia | 2014 |
Can asenapine cause myocarditis?
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Edema; Female; Gastrointestinal Diseases; Heterocyclic Compounds, 4 or More Rings; Humans; Middle Aged; Myocarditis; Schizophrenia | 2015 |
A case of pseudo-Stauffer's syndrome related to asenapine use.
Topics: Alkaline Phosphatase; Antipsychotic Agents; Dibenzocycloheptenes; gamma-Glutamyltransferase; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Diseases; Male; Middle Aged; Paraneoplastic Syndromes; Schizophrenia | 2015 |
The Ireland-Claisen rearrangement strategy towards the synthesis of the schizophrenia drug, (+)-asenapine.
Topics: Antipsychotic Agents; Crystallography, X-Ray; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Models, Molecular; Molecular Structure; Schizophrenia; Stereoisomerism | 2016 |
Changes in Patterns of Utilization and Cost of Health Care Services Associated With Initiation of Asenapine for the Treatment of Schizophrenia in Adults.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Databases, Factual; Dibenzocycloheptenes; Female; Health Services; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Schizophrenia; Young Adult | 2015 |
Asenapine-Induced Acute Dystonia in an Adolescent Male.
Topics: Acute Disease; Administration, Sublingual; Adolescent; Antipsychotic Agents; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Dystonia; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Schizophrenia | 2016 |
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.
Topics: Acute Disease; Computer Simulation; Controlled Clinical Trials as Topic; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Models, Biological; Patient Dropouts; Schizophrenia; Schizophrenic Psychology; Time Factors | 2009 |
Asenapine approved for treatment of schizophrenia, bipolar disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia; United States; United States Food and Drug Administration | 2009 |
Asenapine.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Schizophrenia; United States; United States Food and Drug Administration | 2009 |
New drug information. Saphris.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Dibenzocycloheptenes; Drug Interactions; Heterocyclic Compounds, 4 or More Rings; Humans; Schizophrenia | 2010 |
Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.
Topics: Algorithms; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Biomarkers; Computer Simulation; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Endpoint Determination; Heterocyclic Compounds, 4 or More Rings; Humans; Models, Statistical; Positron-Emission Tomography; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 2011 |
Atypical antipsychotics: the two new arrivals.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Piperidines; Safety; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Update on newer antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Pregnancy; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Asenapine: a new antipsychotic option.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
ACS chemical neuroscience molecule spotlight on Saphris.
Topics: Administration, Sublingual; Akathisia, Drug-Induced; Antipsychotic Agents; Biological Availability; Bipolar Disorder; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Receptors, Neurotransmitter; Schizophrenia | 2010 |
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clinical Trials, Phase III as Topic; Depressive Disorder; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Endpoint Determination; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neurologic Examination; Olanzapine; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Conditioning, Classical; Dibenzocycloheptenes; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Electrophysiology; Heterocyclic Compounds, 4 or More Rings; Injections, Subcutaneous; Male; Microdialysis; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Wistar; Schizophrenia | 2008 |